MedTrace Logo

Contrast-enhanced Ultrasound With Perfluorobutane and Sulfur Hexafluoride for Hepatocellular Carcinoma

NCT04847726 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2021-12-07

No results posted yet for this study

Summary

Intra-individual comparison of diagnostic performance of CEUS With perfluorobutane and sulfur hexafluoride for HCC in high-risk Individuals, and their role in the diagnostic algorithm of HCC.

Conditions

Interventions

DIAGNOSTIC_TEST

contrast enhanced ultrasound

contrast enhanced ultrasound with perfluorobutane and sulfur hexafluoride

DIAGNOSTIC_TEST

Dynamic CT

Participants underwent dynamic CT for hepatic lesion

DIAGNOSTIC_TEST

Liver MRI

Participants underwent liver MRI for hepatic lesion

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Jeong Min Lee, Dr. · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-09
Primary Completion
2021-07-30
Completion
2021-10-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04847726 on ClinicalTrials.gov